Gregory S. Curhan - 02 Mar 2022 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for Gregory S. Curhan
Issuer symbol
ELTX
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 15:20:24 UTC
Previous filing
16 Dec 2021
Next filing
20 Aug 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 02 Mar 2022 Common Stock 100,000 $1.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Chief Financial Officer